

[188] BIOND BIOLOGICS - DEVELOPING UNIQUE, CREATIVE AND BREAKTHROUGH IMMUNOTHERAPIES

Tehila Ben Moshe¹, Ori Shilo¹, Yair Sapir¹, Avidor Shulman¹, Sharon Hashmueli¹, ILANA MANDEL¹, ¹ Biond Biologics

- **Investment Rational**

Biond Biologics is targeting novel immune checkpoints for the treatment of cancer and autoimmune disorders alongside development of a technology enabling targeting intracellular targets with biologics. While the highly prosperous immuno-oncology and autoimmune markets have witnessed major advancements, there is still a great unmet need to find new, more effective therapies, offering exciting opportunities for collaborations, currently pursued by Biond.
- **Business Strategy**

Biond is advancing its novel biologic drug candidates into clinical studies while generating synergistic partnerships with leading companies in the field. For the long term, Biond aims to exploit its intracellular delivery technology and license it to leading pharma companies as well as develop its own pipeline of active agents addressing intracellular, currently “undruggable”, targets.
- **Core Technology**

Biond’s pipeline is based on research of less-charted waters in the fields of immune-checkpoints and immune-evasion. Biond is also developing a novel platform that will enable antibody-targeting of immune factors inside cells. The ability to deliver antibodies into cells will expose a vast array of currently untouchable intra-cellular targets, potentially enhancing the possibilities of treating cancer and other diseases.
- **Product Profile/Pipeline**

Biond is developing innovative drug candidates which elicit anti-tumor immune responses by targeting myeloid cells or by targeting a highly central immune pathway using a novel approach as well as a unique drug candidate for autoimmunity. Biond is advancing its platform for targeting intra-cellular proteins. The projects are at various stages of development, IP protection and collaboration establishment.
- **What's Next?**

Biond plans to advance its different programs towards pre-clinical and clinical stages. In several projects, lead drug products will be selected during 2018. In one project lead drug products have been selected and cell line development will commence soon. Biond is in discussions with various leading companies to create co-development collaborations on its innovative programs which will include financial upside.